Navigation Links
Dermatologists Report Increased Use of Biologics in the Treatment of Psoriasis
Date:6/5/2008

EXTON, Pa., June 5 /PRNewswire/ -- BioTrends Research Group, Inc. released its third annual TreatmentTrends (TM): Psoriasis publication, providing insight into the management of psoriasis. This report is based on responses to an online survey completed by 102 US Dermatologists in April 2008.

According to the study, the majority of Dermatologists reported an increase in their use of biologics for the treatment of psoriasis in the past year, particularly in patients with moderate psoriasis. While the increased use of biologics was seen across the board, certain physician types, particularly those newer to practice, seem to be more aggressive in their use of these agents. Amgen/Wyeth's Enbrel continues to hold its position as market leader amongst the biologics, however, Abbott's Humira has increased its share significantly in the past year, and Dermatologists expect its growth to continue, primarily at the expense of Enbrel. Genentech/Xoma's Raptiva and Astellas' Amevive are rarely used with a collective share of less than 10%.

Despite the increased use of biologics, topical agents remain the most commonly prescribed therapy for psoriasis. Warner Chilcott's Taclonex, continues to hold its position as market leader among topical agents, although Galderma's Clobex is perceived to have significant advantages on certain attributes, most notably around its formulation. While the use of oral agents to treat psoriasis increases with disease severity, less than one-third of patients with severe psoriasis are on oral therapies. Methotrexate and Stiefel's Soriatane are the most commonly prescribed oral agents to treat psoriasis, and each is perceived to have unique advantages and disadvantages. Similar to oral agents, the use of phototherapy to treat psoriasis increases with disease severity, although only about one-fifth of patients with severe psoriasis are receiving phototherapy treatment.

For all treatment types (topicals, orals, biologics), long-term safety is the most important attribute. While all products fall short on this attribute compared to its importance, Dermatologists do perceive there to be significant safety differences between products in each product class, and perceived safety seems to be an important factor in brand preference. Moreover, in a ranking exercise of twelve attributes, "safe when used long term" was the attribute of greatest needs for new products in development to treat psoriasis. Time will tell whether the new IL-12 agents, such as Centocor's ustekinumab and Abbott's ABT-874 will be able to penetrate the TNF alpha inhibitor dominance in the Dermatology setting although interest in these agents is high.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (http://www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... Durham, NC (PRWEB) , ... March 28, 2017 ... ... unwanted side effects and diminished effectiveness over time. A recent study published in ... treat PD by stimulating subventricular zone (SVZ) stem cells to produce more neural ...
(Date:3/28/2017)... VANCOUVER , March 28, 2017 /PRNewswire/ -RepliCel Life Sciences ... is pleased to report compelling safety and clinical data from ... RepliCel,s type 1 collagen-expressing, hair follicle-derived fibroblasts (RCT-01) as a ... ... of establishing a complete safety profile at 6 months and ...
(Date:3/27/2017)... March 27, 2017 Roka Bioscience, Inc. (NASDAQ: ROKA), ... for the detection of foodborne pathogens,  today announced that ... Company Spring 2017 Convention on March 29 at 9:50am ET. ... Marquis. About Roka Bioscience ... Roka Bioscience is ...
(Date:3/27/2017)... Linda, Ca (PRWEB) , ... March 27, 2017 ... ... metastatic colorectal cancer (mCRC) generally produce small, heterogeneous samples with limited tumor content ... analytical challenges remain to be resolved, such as the need for reliable detection ...
Breaking Biology Technology:
(Date:3/2/2017)... Summary This report provides all the ... interests and activities since 2010. ... Read the full report: http://www.reportlinker.com/p03605615-summary/view-report.html ... report provides an in-depth insight into the partnering activity of ... On demand company reports are prepared upon purchase to ensure ...
(Date:2/28/2017)... LOS ANGELES , Feb. 28, 2017   ... identity verification software globally, announces significant enhancements to new ... in May 2016. New products include mobile and desktop ... and DocX TM - a real time manual ... Acuant,s core idScan® technology provides the fastest and most ...
(Date:2/24/2017)... BARCELONA, Spain , Feb. 24, 2017  EyeLock LLC, ... will demonstrate its elite iris biometric solution on ... with X16 LTE at Mobile World Congress ... in Qualcomm,s Booth in Hall 3, Stand ... contains the Qualcomm Haven™ security platform—a combination ...
Breaking Biology News(10 mins):